C

CTI Biopharma Corp
F:CEPS

Watchlist Manager
CTI Biopharma Corp
F:CEPS
Watchlist
Price: 28 EUR
Market Cap: 3.7B EUR

Relative Value

There is not enough data to reliably calculate the relative value of CEPS.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

CEPS Relative Value
Base Case
Not Available
C
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
vs Industry
Median 3Y
53
Median 5Y
50.7
Industry
7.8
vs History
vs Industry
Median 3Y
-58
Median 5Y
-17.2
Industry
24.1
vs History
vs Industry
Median 3Y
-48.8
Median 5Y
-14.5
Industry
21.8
vs History
vs Industry
Median 3Y
-48.6
Median 5Y
-27.5
Industry
23.8
vs History
vs Industry
Median 3Y
-158.4
Median 5Y
-139.1
Industry
3.3
vs History
vs Industry
Median 3Y
53.1
Median 5Y
51
Industry
8
vs History
vs Industry
Median 3Y
56.4
Median 5Y
54.9
Industry
10.3
vs History
vs Industry
Median 3Y
-77.7
Median 5Y
-23.2
Industry
6.3
vs History
vs Industry
Median 3Y
-74.6
Median 5Y
-22.2
Industry
6.7
vs History
vs Industry
Median 3Y
-48.9
Median 5Y
-14.6
Industry
7.9
vs History
vs Industry
Median 3Y
-48.9
Median 5Y
-14.6
Industry
6.3
vs History
vs Industry
Median 3Y
78.6
Median 5Y
57.6
Industry
5.5

Multiples Across Competitors

CEPS Competitors Multiples
CTI Biopharma Corp Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
CTI Biopharma Corp
F:CEPS
3.7B EUR 57.1 -62.5 -83.8 -80.4
FR
Pharnext SCA
OTC:PNEXF
6T USD 33 861 489.7 -160 938.6 -195 430.8 -193 200.7
US
Abbvie Inc
NYSE:ABBV
400.9B USD 6.7 170.7 16.5 23.4
US
Amgen Inc
NASDAQ:AMGN
176.1B USD 4.9 25.1 18.1 18.1
US
Gilead Sciences Inc
NASDAQ:GILD
154.4B USD 5.3 19 12.8 12.8
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
115.9B USD 9.9 31.5 23.1 24.2
US
Epizyme Inc
F:EPE
94.1B EUR 2 080.5 -530.9 -578.1 -562.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
80.9B USD 5.7 17.7 16.8 19.1
AU
CSL Ltd
ASX:CSL
85.6B AUD 3.6 18.9 12.7 15.9
NL
argenx SE
XBRU:ARGX
44.8B EUR 14.6 34.3 59.1 60.8
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
52.7B USD 16.4 1 210.8 159.1 192.9
P/S Multiple
Revenue Growth P/S to Growth
US
C
CTI Biopharma Corp
F:CEPS
Average P/S: 3 078 517.7
57.1
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
33 861 489.7
N/A N/A
US
Abbvie Inc
NYSE:ABBV
6.7
9%
0.7
US
Amgen Inc
NASDAQ:AMGN
4.9
5%
1
US
Gilead Sciences Inc
NASDAQ:GILD
5.3
4%
1.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
9.9
10%
1
US
E
Epizyme Inc
F:EPE
2 080.5
N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
5.7
6%
0.9
AU
CSL Ltd
ASX:CSL
3.6
5%
0.7
NL
argenx SE
XBRU:ARGX
14.6
49%
0.3
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
16.4
46%
0.4
P/E Multiple
Earnings Growth PEG
US
C
CTI Biopharma Corp
F:CEPS
Average P/E: 191
Negative Multiple: -62.5
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -160 938.6 N/A N/A
US
Abbvie Inc
NYSE:ABBV
170.7
89%
1.9
US
Amgen Inc
NASDAQ:AMGN
25.1
45%
0.6
US
Gilead Sciences Inc
NASDAQ:GILD
19
190%
0.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
31.5
N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -530.9 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.7
9%
2
AU
CSL Ltd
ASX:CSL
18.9
11%
1.7
NL
argenx SE
XBRU:ARGX
34.3
40%
0.9
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
1 210.8
N/A N/A
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
C
CTI Biopharma Corp
F:CEPS
Average EV/EBITDA: 39.8
Negative Multiple: -83.8
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -195 430.8 N/A N/A
US
Abbvie Inc
NYSE:ABBV
16.5
14%
1.2
US
Amgen Inc
NASDAQ:AMGN
18.1
11%
1.6
US
Gilead Sciences Inc
NASDAQ:GILD
12.8
7%
1.8
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
23.1
16%
1.4
US
E
Epizyme Inc
F:EPE
Negative Multiple: -578.1 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
16.8
11%
1.5
AU
CSL Ltd
ASX:CSL
12.7
8%
1.6
NL
argenx SE
XBRU:ARGX
59.1
807%
0.1
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
159.1
N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
C
CTI Biopharma Corp
F:CEPS
Average EV/EBIT: 45.9
Negative Multiple: -80.4
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -193 200.7 N/A N/A
US
Abbvie Inc
NYSE:ABBV
23.4
30%
0.8
US
Amgen Inc
NASDAQ:AMGN
18.1
20%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
12.8
12%
1.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
24.2
16%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -562.7 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
19.1
13%
1.5
AU
CSL Ltd
ASX:CSL
15.9
11%
1.4
NL
argenx SE
XBRU:ARGX
60.8
N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
192.9
N/A N/A